This video highlights a study that establishes mutated CALR as a myeloproliferative neoplasms–specific tumor antigen and provides a rationale for the development of immunotherapies targeting mutated CALR.
Cansu Cimen Bozkus, PhD
Advertisement
Articles by Cansu Cimen Bozkus, PhD
Advertisement
Latest Updated Articles
Immunotherapies Could Play Role in CALR-Positive Myeloproliferative NeoplasmsPublished: December 28th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
2
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
3
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
4
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
5
